Legislative Alert: Petco Plaintiffs Seek Class | Uber Improves Checks | Sessions Pressures Drug Makers [Video]
- Petco Faces Class Action over Credit Checks
- Uber Boosts Security Efforts
- Sessions Pressures Drug Companies
Petco Faces Class Action over Credit Checks
Plaintiffs seeking class status are accusing Petco of failing to provide a “clear and conspicuous" disclosure of background checks in their online applications. The disclosure, which appears in a text box in the middle of the application, requires applicants to scroll through pages of small text. According to the lawsuit, when printed out, the disclosure takes up five full pages. In addition to this alleged FCRA violation, the two named plaintiffs claim the company made adverse hiring decisions based on credit report information without offering any type of adverse action process. Last June, the company asked the judge to dismiss the complaint citing the Spokeo ruling, and saying the plaintiffs did not allege concrete harm. The judge decided the case will go forward.
[Related] FCRA Compliance: What You Need to Know
Uber Boosts Security Efforts
Uber has a new CEO, and he is working to make the whole process safer for both riders and drivers. The ride-share company has already announced plans to start conducting annual background checks on current drivers instead of relying on just one pre-hire check. In addition to constantly monitoring for criminal arrests and moving violations, safety upgrades are also coming to the app. A button inside the app will call 911, and there are other refinements to help riders share their location with loved ones. Background checks will continue to focus on court records and databases instead of fingerprints, something Uber has long believed in.
Sessions Pressures Drug Companies
Attorney General Jeff Sessions has proposed some new regulations that could limit how many opioid pain relievers are on the market. The goal is to crack down on illegitimate prescriptions for the highly addictive drugs. The regulations will require drug companies to work with the Drug Enforcement Administration (DEA), the Centers for Disease Control and Prevention (CDC) and other federal and local governments to limit the amount of opioids they can send to providers. If the DEA thinks a company’s drugs are being diverted or misused, the government will reduce the amount of drugs they can make.